20 Oct 2015 07:48![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
Mon, 04th Apr 2016 11:47
(ShareCast News) - Scancell Holdings's losses increased marginally in the year ended 30 April 2015. The cancer immunotherapy developer announced on Friday a wider loss of £2.414m from £2.222m last year. It comes as a result of expected additional expenditure on its SCIB1 ImmunoBody clinical trials
Read moreBiopharmaceutical company Scancell Holdings reported further encouraging results from the ongoing 'Phase 1/2' clinical trial of its melanoma treatment SCIB1, which it presented at the annual meeting of the American Society of Clinical Oncology in Chicago. The data showed that all 16 patients with re
Read more